Controversial Vaccine Trial in Guinea-Bissau Gets Green Light 2026

A controversial vaccine trial in Guinea-Bissau that will withhold hepatitis B vaccines from some newborns has received approval to proceed, drawing sharp criticism from ethicists and public health experts. The trial, supported by US Health Secretary Robert F. Kennedy Jr., aims to study the effects of delaying the hepatitis B vaccine birth dose.

The Trial and Its Controversial Design

The Danish-led trial plans to enroll 14,000 infants in Guinea-Bissau. Half will receive the hepatitis B vaccine at birth, while the other half will not receive it until six weeks of age. This design has raised significant ethical concerns because the hepatitis B vaccine is recommended at birth by the World Health Organization to prevent mother-to-child transmission of the virus, which can lead to chronic liver disease and liver cancer.

RFK Jr.'s Vaccine Vision

Robert F. Kennedy Jr., a longtime vaccine opponent, has praised the researchers behind the trial and touted it as part of the Trump administration's vaccine agenda. Kennedy has suggested that the US should reconsider its own birth dose policy, despite overwhelming evidence of the vaccine's safety and effectiveness. At an anti-vaccine conference last month, he highlighted the trial as exemplifying US-supported research.

Ethical Concerns and Expert Reactions

Experts argue that such a trial would never be approved in the US due to ethical violations. Dr. Paul Offit, an infectious disease physician at Children's Hospital of Philadelphia, criticized the trial, stating, "He's taking advantage of a developing country … Is it because children in Africa are more expendable than children here?" The trial's approval by the University of Southern Denmark's ethics committee has sparked outrage among bioethicists who question the exploitation of vulnerable populations.

Comparison of Vaccine Policies

Key Takeaways

• The trial will withhold hepatitis B vaccines from 7,000 newborns in Guinea-Bissau.
• RFK Jr. supports the trial as part of a broader vaccine skepticism agenda.
• Ethicists argue the trial exploits vulnerable populations and violates medical ethics.
• The trial could undermine global trust in vaccine safety and efficacy.

Implications for Global Health

If the trial proceeds, it may set a dangerous precedent for conducting ethically questionable research in developing countries. It also threatens to erode public confidence in vaccines, which are critical for preventing deadly diseases. The World Health Organization has expressed concern over any delay in the birth dose, emphasizing that timely vaccination saves lives.

FAQ